- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/64 - Relaxines
Détention brevets de la classe C07K 14/64
Brevets de cette classe: 119
Historique des publications depuis 10 ans
|
8
|
10
|
11
|
15
|
7
|
11
|
8
|
12
|
10
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Ambrx, Inc. | 192 |
14 |
| Bristol-myers Squibb Company | 4877 |
10 |
| MedImmune Limited | 625 |
9 |
| Sanofi | 3975 |
9 |
| The Scripps Research Institute | 1354 |
8 |
| Immatics Biotechnologies GmbH | 1176 |
5 |
| Modernatx, Inc. | 1205 |
5 |
| Chemical & Biopharmaceutical Laboratories of Patras S.A. | 27 |
4 |
| Florey Institute of Neuroscience and Mental Health | 45 |
4 |
| Howard Florey Institute of Experimental Physiology and Medicine | 19 |
4 |
| Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | 6 |
4 |
| Tectonic Therapeutic, Inc. | 6 |
4 |
| Eli Lilly and Company | 3738 |
3 |
| River 2 Renal Corp. | 3 |
3 |
| Bayer Intellectual Property GmbH | 2565 |
2 |
| Adaptimmune Limited | 178 |
2 |
| National University of Singapore | 2381 |
2 |
| The University of Queensland | 656 |
2 |
| F. Hoffmann-La Roche AG | 7961 |
1 |
| AstraZeneca AB | 2968 |
1 |
| Autres propriétaires | 23 |